

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- ✓ • BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITE DE COOPERATION EN MATIÈRE DE BREVETS (PCT)

(51) Classification internationale des brevets ⁶ : C07K 14/435, A01N 63/02, A61K 38/17		A2	(11) Numéro de publication internationale: WO 97/30082
			(43) Date de publication internationale: 21 août 1997 (21.08.97)
(21) Numéro de la demande internationale: PCT/FR97/00295 (22) Date de dépôt international: 17 février 1997 (17.02.97) (30) Données relatives à la priorité: 96/02168 16 février 1996 (16.02.96) FR (71) Déposant (pour tous les Etats désignés sauf US): RHONE-POULENC AGROCHIMIE [FR/FR]; 14/20, rue Pierre-Baizet, F-69009 Lyon (FR). (72) Inventeurs; et (75) Inventeurs/Déposants (US seulement): BULET, Philippe [FR/FR]; 11, rue du Cottage, F-67550 Vendenheim (FR). HETRU, Charles [FR/FR]; 5, rue des Moineaux, F-67400 Illkirch Graffenstaden (FR). HOFFMANN, Jules [FR/FR]; 5, rue Closener, F-67000 Strasbourg (FR). SABATIER, Laurence [FR/FR]; 8, rue des Vergers, F-67120 Molsheim (FR). (74) Mandataire: CHRETIEN, François; Rhône-Poulenc Agrochimie - D.P.I., 14/20, rue Pierre-Baizet, F-69009 Lyon (FR).		(81) Etats désignés: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, brevet ARIPO (KE, LS, MW, SD, SZ, UG), brevet eurasién (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Publiée Sans rapport de recherche internationale, sera republiée dès réception de ce rapport.	
(54) Title: ANTIFUNGIC AND ANTIBACTERIAL PEPTIDE (54) Titre: PEPTIDE ANTIBACTERIEN ET ANTIFONGIQUE (57) Abstract The invention discloses an antibacterial and antifungic peptide having the formula (I). (57) Abrégé Peptide antibactérien et antifongique de la formule (I), utilisable comme antibactérien et antifongique.			

Arg Ser Val Cys Arg Gln Ile Lys Ile Cys Arg

|

Arg

|

Arg

|


Tyr Pro Arg Asn Thr Cys Lys Tyr Tyr Cys Gly Gly

(I)

REVENDICATIONS

5

1. Peptide de formule:



2. Composition antibactérienne, caractérisée en ce qu'elle contient comme matière active un peptide selon la revendication 1.

15

3. Composition selon la revendication 2, utilisable pour la protection des plantes contre les bactéries pathogènes.

4. Composition selon la revendication 2, utilisable pour le traitement thérapeutique du corps humain ou animal.

20

5. Composition antifongique, caractérisée en ce qu'elle contient comme matière active un peptide selon la revendication 1.

6. Composition selon la revendication 5, utilisable pour la protection des plantes contre les bactéries pathogènes.

7. Composition selon la revendication 5, utilisable pour le traitement thérapeutique du corps humain ou animal.

30

8. Procédé pour la protection des plantes contre les maladies bactériennes, caractérisé en ce qu'on applique, comme matière active, un peptide selon la revendication 1.

9. Procédé pour la protection des plantes contre les maladies fongiques, caractérisé en ce qu'on applique, comme matière active, un peptide selon la revendication 1.

35

10. Procédé de préparation du peptide selon la revendication 1, caractérisé en ce que, successivement:

a) on prélève de l'hémolymph du scorpion *Androctonus australis* ;
b) on effectue l'extraction par mise en contact d'hémolymph ou d'un broyat de *Androctonus australis* obtenues précédemment avec un milieu acide à neutre sous agitation, puis par centrifugation;

5 c) on fractionne le surnageant avec séparation par lavage des molécules hydrophiles et élution des molécules hydrophobes par des éléments appropriés, sur colonne séparatrice;

d) on purifie les extraits;

e) on effectue le séquençage.

10



DEMANDE INTERNATIONALE PUBLIEE EN VERTU DU TRAITE DE COOPERATION EN MATIERE DE BREVETS (PCT)

<p>(51) Classification internationale des brevets ⁶ : C07K 14/435, A01N 63/02, A61K 38/17</p>	<p>A3</p>	<p>(11) Numéro de publication internationale: WO 97/30082 (43) Date de publication internationale: 21 août 1997 (21.08.97)</p>
<p>(21) Numéro de la demande internationale: PCT/FR97/00295 (22) Date de dépôt international: 17 février 1997 (17.02.97) (30) Données relatives à la priorité: 96/02168 16 février 1996 (16.02.96) FR (71) Déposant (pour tous les Etats désignés sauf US): RHONE-POULENC AGROCHIMIE [FR/FR]; 14/20, rue Pierre-Baizet, F-69009 Lyon (FR). (72) Inventeurs; et (75) Inventeurs/Déposants (US seulement): BULET, Philippe [FR/FR]; 11, rue du Cottage, F-67550 Vendenheim (FR). HETRU, Charles [FR/FR]; 5, rue des Moineaux, F-67400 Illkirch Graffenstaden (FR). HOFFMANN, Jules [FR/FR]; 5, rue Closener, F-67000 Strasbourg (FR). SABATIER, Laurence [FR/FR]; 8, rue des Vergers, F-67120 Molsheim (FR). (74) Mandataire: CHRETIEN, François; Rhône-Poulenc Agrochimie - D.P.I., 14/20, rue Pierre-Baizet, F-69009 Lyon (FR).</p>		<p>(81) Etats désignés: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, brevet ARIPO (KE, LS, MW, SD, SZ, UG), brevet eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Publiée <i>Avec rapport de recherche internationale. Avant l'expiration du délai prévu pour la modification des revendications, sera republiée si de telles modifications sont reçues.</i> (88) Date de publication du rapport de recherche internationale: 25 septembre 1997 (25.09.97)</p>

(54) Title: ANTIFUNGIC AND ANTIBACTERIAL PEPTIDE


(54) Titre: PEPTIDE ANTIBACTERIEN ET ANTIFONGIQUE

(57) Abstract

The invention discloses an antibacterial and antifungal peptide having the formula (I).

(57) Abbrégé

Peptide antibactérien et antifongique de la formule (I), utilisable comme antibactérien et antifongique.



INTERNATIONAL SEARCH REPORT

National Application No
PCT/FR 97/00295

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/435 A01N63/02 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 194, no. 1, 15 July 1993, ORLANDO, FL US, pages 17-22, XP002018845 COCIANCICH E.A.: "Purification and characterization of a scorpion defensin, a 4 kDa antibacterial peptide presenting structural similarities with insect defensins and scorpion toxins " see the whole document --- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

31 July 1997

Date of mailing of the international search report

07.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

national Application No
PCT/FR 97/00295

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 47, 22 November 1996, MD US, pages 29537-29544, XP002036559 EHRET-SABATIER E.A.: "CHARACTERIZATION OF NOVEL CYSTEINE-RICH ANTIMICROBIAL PEPTIDES FROM SCORPION BLOOD" see the whole document -----</p>	1-10

- Arg Ser Val Cys Arg Gln Ile Lys Ile Cys Arg
Tyr Pro Arg Asn Thr Cys Lys Tyr Tyr Cys Gly Gly

10. Procedure for the preparation of the peptide according to Claim 1, characterized in that, successively:

- a) Hemolymph is taken from the *Androctonus australis* scorpion;
- b) Extraction is performed by placing hemolymph or finely ground material, as previously obtained from *Androctonus australis*, in contact with an acidic-to-neutral solution, first via stirring and then via centrifugation;
- 5 c) The supernatant liquid is fractionated, with separation via the washing of the hydrophilic molecules and elution of the hydrophobic molecules, through the use of appropriate agents, on a separation column;
- d) The extracts are purified; and
- e) Sequencing is performed.

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199718843 B2
(10) Patent No. 722891

(54) Title
Antifungic and antibacterial peptide

(51)⁷ International Patent Classification(s)
C07K 014/435 A61K 038/17
A01N 063/02

(21) Application No: 199718843

(22) Application Date: 1997.02.17

(87) WIPO No: WO97/30082

(30) Priority Data

(31) Number	(32) Date	(33) Country
96/02168	1996.02.16	FR

(43) Publication Date : 1997.09.02

(43) Publication Journal Date : 1997.10.30

(44) Accepted Journal Date : 2000.08.10

(71) Applicant(s)
Rhone-Poulenc Agrochimie

(72) Inventor(s)
Philippe Bulet; Charles Hetru; Jules Hoffmann; Laurence Sabatier

(74) Agent/Attorney
DAVIES COLLISON CAVE, 1 Little Collins Street, MELBOURNE VIC 3000

OPI DATE 02/09/97 APPLN. ID 18843/97
AOJP DATE 30/10/97 PCT NUMBER PCT/FR97/00295



DEM

AU9718843

(PCT)

(51) Classification internationale des brevets :

C07K 14/435, A01N 63/02, A61K 38/17

A2

(11) Numéro de publication internationale:

WO 97/30082

(43) Date de publication internationale:

21 août 1997 (21.08.97)

(21) Numéro de la demande internationale: PCT/FR97/00295

(22) Date de dépôt international: 17 février 1997 (17.02.97)

(30) Données relatives à la priorité:
96/02168 16 février 1996 (16.02.96) FR

(71) Déposant (pour tous les Etats désignés sauf US): RHONE-POULENC AGROCHIMIE [FR/FR]; 14/20, rue Pierre-Baizet, F-69009 Lyon (FR).

(72) Inventeurs; et

(75) Inventeurs/Déposants (US seulement): BULET, Philippe [FR/FR]; 11, rue du Cottage, F-67550 Vendenheim (FR). HETRU, Charles [FR/FR]; 5, rue des Moineaux, F-67400 Illkirch Graffenstaden (FR). HOFFMANN, Jules [FR/FR]; 5, rue Closener, F-67000 Strasbourg (FR). SABATIER, Laurence [FR/FR]; 8, rue des Vergers, F-67120 Molsheim (FR).

(74) Mandataire: CHRETIEN, François; Rhône-Poulenc Agrochimie - D.P.I., 14/20, rue Pierre-Baizet, F-69009 Lyon (FR).

(81) Etats désignés: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, brevet ARIPO (KE, LS, MW, SD, SZ, UG), brevet eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Publiée

Sans rapport de recherche internationale, sera republiée dès réception de ce rapport.

(54) Title: ANTIFUNGIC AND ANTIBACTERIAL PEPTIDE


(54) Titre: PEPTIDE ANTIBACTERIEN ET ANTIFONGIQUE

(57) Abstract

The invention discloses an antibacterial and antifungic peptide having the formula (I).

(57) Abrégé

Peptide antibactérien et antifongique de la formule (I), utilisable comme antibactérien et antifongique.



Antibacterial and antifungal peptide

The present invention relates to a novel protein-rich peptide with antibacterial and antifungal properties, and to compositions, which can be used in agriculture and in human or animal therapy, containing this peptide as active material. The invention also relates to processes for treating plants using these compositions, as well as to processes for preparing this peptide.

It has been known for a long time that insects have effective resistance to bacteria. This defence is largely based on the rapid synthesis of several families of peptides. This defence is due to the rapid synthesis of several families of peptides with a broad spectrum of activity. This synthesis is induced by a septic wound or by the injection of a low dose of bacteria. Among the antibacterial peptides induced, those best characterized are the insect cecropines and defensins. Several other antibacterial peptides have been partially characterized.

Apart from the insect class, little is known about other arthropods. Scorpions have existed far longer than insects in terms of phylogeny.

A peptide has now been isolated, from an induction in the scorpion *Androctonus australis*, this peptide showing remarkable characteristics as well as antibacterial and antifungal properties.



More particularly, a first aspect of the invention relates to the peptide of formula I:

Arg Ser Val Cys Arg Gln Ile Lys Ile Cys Arg

Arg

Arg

Tyr Pro Arg Asn Thr Cys Lys Tyr Tyr Cys Gly Gly

Hereinbelow, the molecule of formula I will be referred to as androctonine. This relatively small molecule contains 4 cysteine residues engaged in two intramolecular bridges.

Another aspect of the invention relates to a first process for obtaining and isolating the above peptide, in which the following are successively carried out:

- a) hemolymph is taken from the scorpion *Androctonus australis*;
- b) extraction is carried out by placing the *Androctonus australis* hemolymph obtained above in contact with an acid medium, with stirring, followed by centrifugation;
- c) the supernatant is fractionated with separation by washing of the hydrophilic molecules and elution of the hydrophobic molecules with appropriate components on a separating column;
- d) the extracts are purified;
- e) the peptide is characterized.



The hemolymph is taken by incision of the cuticle. It is collected in a tube containing a protease inhibitor. After centrifugation to remove the blood cells, the plasma is stored at -30°C.

5 In a preferred manner, in the second step (extraction), the *Androctonus australis* hemolymph is placed in contact with an acidic medium consisting of an acidic solution of an acid (of pH 2). The solution can be a solution of an inorganic or organic acid such
10 as, for example, trifluoroacetic acid. The extract obtained is then centrifuged under cold conditions at a speed of 30,000 x g at 4°C for 25 min.


Preferably, in the third step (fractionation), the extract is placed on a reverse-
15 phase cartridge in order to carry out a solid-phase extraction. The water-soluble molecules are washed out with a dilute acid solution and the hydrophobic molecules are eluted with an appropriate eluent. Good results are obtained with trifluoroacetic acid for the
20 washing and an eluent containing increasing amounts of acetonitrile in dilute acid solution.

Preferably, the fourth step (purification) is carried out with a suitable eluent which can be identical to or different from the one in the preceding
25 stage.


Preferably, in the final step (characterization), the nature of the peptide is analyzed by the method of sequencing by Edman



degradation (Acta Chemica Scandinavia 10 (1956) pp. 761-768). According to this method, the following structures are obtained:



No signal was detectable in positions 4, 10, 16 and 20 (Edman degradation). The presence of cysteines in these positions was shown by mass spectrometry, the structure thus obtained being as follows:



The measured masses for androctonine above are, respectively:

$$3076.65 \pm 0.24 \text{ Da}$$

However, the masses calculated on the basis of sequencing data are, respectively:

$$3080.65 \pm 0.24 \text{ Da}$$


The difference in mass corresponds to the formation of two intramolecular disulfide bridges.

In order to establish the connectivity of the disulfide bridges, the molecule was cleaved with an



enzyme, Lys-C endoproteinase, which breaks the peptide chain after lysine. The peptides obtained were isolated and mass spectrometry showed that they were two peptides linked by a disulfide bridge. The sequences deduced were Arg Ser Val Cys Arg Gln Ile Lys plus Cys Thr Asn Arg Asn Pro Tyr and Ile Cys Arg Arg Arg Gly Gly Cys Tyr Tyr.

The connectivity of the disulfide bridges is thus established and cysteine 1 is linked to cysteine 4, cysteine 2 to cysteine 3. This result can be schematized thus:



These good correlations confirm the proposed sequences.

The peptides according to the invention can also be obtained without difficulty according to a second process, by Fmoc chemical synthesis (Atherton and Sheppard R.C. (1989), Solid Phase Peptide Synthesis (IRL, Oxford, UK)) followed by renaturing in 100 mM ammonium acetate solution at pH 8.5 for 24 hours with stirring at room temperature. The androctonine obtained has the same chromatographic properties as the native molecule and the connectivity of the disulfide bridges is identical to that of the natural molecule. The mass measured after renaturing (3076.61 ± 0.67) is very



similar to that of the native molecule. The synthetic molecule has the same antibacterial activity as the native molecule on the bacterium *Micrococcus luteus*.

All of the antibacterial and hemolytic tests
5 are carried out with the synthetic molecule.

1. Androctonine has no lytic effect on porcine or bovine red blood cells.

2. These molecules have antibacterial properties on Gram-negative and Gram-negative bacteria
10 (cf. Table 1), phytopathogenic bacteria and phytopathogenic fungi.

The examples which follow illustrate the production and the antibacterial properties of the peptides and the compositions according to the
15 invention.

Example 1: Isolation and characterization of the peptide

The process is performed according to the following steps:

20 - extraction and purification:

The hemolymph (3.8 ml) is taken by incision of the cuticle. It is transferred into a tube, which is kept cold, in the presence of a protease inhibitor (aprotinine) and then centrifuged at $30,000 \times g$ for
25 25 minutes at 4°C . The supernatant thus obtained is immediately subjected to various purification steps.



Fractionation of the extract on Sep-Pak C18 cartridges

After depositing the extract on Sep-Pak C18 cartridges, the molecules of hydrophilic nature are
5 removed by simple washing with 5 ml of water acidified with 0.05% trifluoroacetic acid (TFA).

The hydrophobic molecules are eluted with 10, 40 and 80% solutions of acetonitrile in acidified water (0.05% TFA, 5 ml per cartridge).

10 The fractions collected are named "10% elution", "40% elution" and "80% elution" and are concentrated under vacuum. The fractions are then reconstituted with HPLC-grade water before HPLC analysis.

15 *HPLC purification of the molecules with antibacterial activity*

First step:

The "40% elution" fraction is analyzed on an Aquapore OD 300 C18 reverse-phase column with a linear
20 gradient of from 2 to 52% acetonitrile in acidified water (0.05% TFA) over 90 minutes (i.e. an increase of 0.44% acetonitrile per minute) at a flow rate of 1 ml/min.

The resulting active fractions are then
25 purified on a "high pressure inert" (HPI) Delta Pak C18 column (150*3.9 mm).

The elution is carried out in a linear two-phase gradient of from 2 to 11% acetonitrile in



acidified water (6 mM HCl) over 10 minutes and from 11 to 21% over 50 min at a flow rate of 1 ml/min. The purity of the active fraction is controlled by capillary electrophoresis before determination of the sequence by Edman degradation and analysis by mass spectrometry.

Example 2: in vitro test: measurement of the antibacterial activity by microspectrophotometry

Pure each strain of bacteria used (E. coli; M. luteus), an isolated column is suspended in 10 ml of DIFCO PB medium (Poor Broth, Luria Bertani medium free of yeast extract) and incubated at 30°C overnight with slow stirring.

The bacteria to be tested are brought to an optical density at 600 nm of 0.001 in fresh culture medium. 10 µl of each fraction is deposited in microtitration plates in the presence of 100 µl of the bacterial suspension. After incubation for 24 hours at 25°C, the growth is evaluated by measuring the absorbance at 600 nm using a microtitration plate reader.

Under these conditions, a 50% inhibition is observed at the concentrations, expressed in µM, indicated in the following table:



Table 1

	Gram +/-	Androctonine MIC (μ M)
Bacteria		
<i>Micrococcus luteus</i>	+	0.6-1.5
<i>Aerococcus viridans</i>	+	0.3-0.6
5 <i>Bacillus subtilis</i>	+	1.5-3.0
<i>Staphylococcus aureus</i>	+	15-30
<i>Clavibacter michi ganensis</i>	+	6-15
<i>Escherichia coli</i> D22	-	>30
<i>Escherichia coli</i> D31	-	3-6
10 <i>Escherichia coli</i> 1106	-	6-15
<i>Salmonella typhimurium</i>	-	3-6

Using the same protocol but with
phytopathogenic bacteria, the following results are
obtained:



Table 2

		Androctonine MIC (μ M)
	Bacteria	
	<i>Clavibacter michiganensis</i>	6-15
	<i>Pseudomonas syringae</i>	0.5-1
5	<i>Pseudomonas syringae</i> pv <i>syringae</i>	15-22
	<i>Pseudomonas pisi</i>	6-15
	<i>Pseudomonas maculicola</i>	3-6
	<i>Pseudomonas valerianella</i>	15-22
	<i>Pseudomonas syr phaseoli</i>	2-4
10	<i>Xanthomonas campestris</i> pv <i>campestris</i>	3-6
	<i>Xanthomonas vesicatoria</i> 687.3	1.5-3
	<i>Xanthomonas vesicatoria</i> B229RI	1.5-3
	<i>Xanthomonas phaseolica</i>	1-2

Using the same protocol but with
 15 phytopathogenic fungi, the following results are
 obtained:



Table 3

	Androctonine	
	MIC (μ M)	
Fungi	without salts	with salts*
<i>Alternaria dauci</i>	4.1-8.2	16-32
<i>Stemphyllium</i>	4-8	16-32
5 <i>Fusarium oxysporum</i> L	2-4	>32
<i>Verticilium toreillis</i>	2-4	>32
<i>Botrytis petuniae</i>	4-8	>32
<i>Fusarium oxysporum meloni</i>	2-4	-

* medium supplemented with 1 mM CaCl_2 and

10 20 mM KCl

Among the crops which can undergo an antibacterial treatment using a compound according to the invention, mention may be made, for example, of rice, cereals, in particular wheat and barley, as well
 15 as arboricultural, fruit-yielding and legume-yielding plants.

Among the crops which can undergo an antifungal treatment using a compound according to the invention, mention may be made, for example, of
 20 Cucurbitaceae, floral cultures (petunia) and market



garden crops (carrots, tomatoes, cabbages).

These results show the excellent
antibacterial activity of the peptide according to the
invention, which can be applied to the human, animal
5 and plant fields.

The subject of the present invention is also
compositions, which can be used as antibacterial
agents, containing as active material(s) one (or more)
compound(s) according to the invention as described
10 above, mixed with solid or liquid agriculturally
acceptable supports and surfactants that are also
agriculturally acceptable. In particular, the common
inert supports and the common surfactants can be used.
These compositions cover not only compositions ready
15 for application to the crop to be treated using a
suitable device, such as a spraying device, but also
concentrated commercial compositions which must be
diluted before application to the crop.

These compositions can also contain other
20 ingredients of any kind such as, for example,
protective colloids, adhesives, thickeners, thixotropic
agents, penetration agents, stabilizers, sequestering
agents, etc. More generally, the compounds used in the
invention can be combined with any solid or liquid
25 additive corresponding to the usual formulating
techniques.

In general, the compositions according to the
invention usually contain from 0.05 to 95%



approximately (by weight) of a compound according to the invention (hereinafter referred to as active material), one or more solid or liquid supports and, optionally, one or more surfactants.

5 In the present specification, the term "support" denotes a natural or synthetic, organic or inorganic material with which the compound is combined in order to facilitate its application to the plant, to seeds or the soil. This support is thus generally inert
10 and it should be agriculturally acceptable, in particular on the plant treated. The support can be solid (clays, natural or synthetic silicates, silica, resins, waxes, solid fertilizers, etc.) or liquid (water, alcohols, in particular butanol, etc.).

15 The surfactant can be an emulsifier, dispersant or wetting agent of ionic or nonionic type or a mixture of such surfactants. Mention may be made, for example, of polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic or naphthalenesulfonic acid
20 salts, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (in particular alkylphenols or arylphenols), salts of sulfosuccinic acid esters, taurine derivatives (in particular alkyl taurates),
25 polyoxyethylated phosphoric esters of alcohols or of phenols, fatty acid esters of polyols, derivatives containing sulfate, sulfonate and phosphate functions of the above compounds. The presence of at least one



surfactant is generally essential when the compound and/or the inert support are not water-soluble and when the vector agent for the application is water.

Thus, the compositions for agricultural use according to the invention can contain the active materials according to the invention in a very wide range, of from 0.05% to 95% (by weight). Their surfactant content is advantageously between 5% and 40% by weight.

10 These compositions according to the invention are themselves in quite diverse solid or liquid forms.

As solid composition forms, mention may be made of powders for dusting (with a compound content which can be up to 100%) and granules, in particular 15 those obtained by extrusion, compacting, impregnation of a granular support or by granulation of a powder (the compound content of these granules being between 0.5 and 80% for the latter cases), and effervescent tablets or lozenges.

20 The peptide according to the invention can also be used in the form of powders for dusting; a composition comprising 50 g of active material and 950 g of talc can also be used; a composition comprising 20 g of active material, 10 g of finely 25 divided silica and 970 g of talc can also be used; these constituents are mixed together and ground and the mixture is applied by dusting.

As liquid composition forms or forms intended



to constitute liquid compositions during application, mention may be made of solutions, in particular water-soluble concentrates, emulsifiable concentrates, emulsions, concentrated suspensions, aerosols, wettable
5 powders (or powder for spraying), pastes and gels.

The emulsifiable or soluble concentrates usually comprise 10 to 80% active material, whereas the emulsions or solutions ready for application contain 0.001 to 20% active material.

10 In addition to the solvent, the emulsifiable concentrates can contain, when necessary, 2 to 20% of appropriate additives such as the stabilizers, surfactants, penetration agents, corrosion inhibitors, dyes or adhesives mentioned above.

15 Using these concentrates, emulsions of any desired concentration can be obtained by dilution with water, these emulsions being particularly suitable for application to crops.

The composition of a number of emulsifiable
20 concentrates is given hereinbelow by way of example:

Example EC 1:

- active material	400 g/l
- alkaline dodecylbenzene sulfonate	24 g/l
25 - nonylphenol oxyethylated with 10 molecules of ethylene oxide	16 g/l
- cyclohexanone	200 g/l
- aromatic solvent	qs 1 litre



According to another emulsifiable concentrate formula, the following are used:

Example EC 2

	- active material	250 g
5	- epoxidized plant oil	25 g
	- mixture of alkyl aryl sulfonate and of polyglycol fatty alcohol ether	100 g
	- diAndhylformamide	50 g
10	- xylene	575 g

The concentrated suspensions, which can also be applied by spraying, are prepared so as to obtain a stable fluid product which does not deposit, and they usually contain from 10 to 75% active material, from
 15 0.5 to 15% surfactants, from 0.1 to 10% thixotropic agents and from 0 to 10% suitable additives, such as anti-foam agents, corrosion inhibitors, stabilizers, penetration agents and adhesives, and, as support, water or an organic liquid in which the active material
 20 is only sparingly soluble or is insoluble: certain solid organic materials or inorganic salts can be dissolved in the support in order to help prevent sedimentation, or as antifreezes for the water.

By way of example, here is a concentrated
 25 suspension composition:

Example CS 1:

- active material	500 g
-------------------	-------



	- polyethoxylated tristyrylphenol	
	phosphate	50 g
	- polyethoxylated alkylphenol	50 g
	- polysodium carboxylate	20 g
5	- ethylene glycol	50 g
	- organopolysiloxane oil	
	(antifoaming agent)	1 g
	- polysaccharide	1.5 g
	- water	316.5 g

10 The wettable powders (or powder for spraying)
are usually prepared such that they contain 20 to 95%
active material, and they usually contain, in addition
to the solid support, from 0 to 30% of a wetting agent,
from 3 to 20% of a dispersant and, where necessary,
15 from 0.1 to 10% of one or more stabilizers and/or other
additives, such as penetration agents, adhesives,
anticaking agents, dyes, etc.

 In order to obtain the powders for spraying
or the wettable powders, the active materials are
20 intimately mixed with the additional substances in
suitable mixers and are ground in mills or other
suitable grinders. Powders for spraying are thus
obtained with advantageous wettability and suspension
formation; they can be suspended in water at any
25 desired concentration and these suspensions can be used
very advantageously in particular for application to
plant leaves.

Pastes can be prepared instead of wettable



powders. The conditions and methods for preparing and using these pastes are similar to those for the wettable powders or powders for spraying.

By way of example, here are various compositions of wettable powders (or powders for spraying):

Example WP 1

	- active material	50%
	- ethoxylated fatty alcohol	
10	(wetting agent)	2.5%
	- ethoxylated phenylethylphenol	
	(dispersant)	5%
	- chalk (inert support)	42.5%

Example WP 2:

15	- active material	10%
	- synthetic C13 oxo alcohol of branched type, ethoxylated with 8 to 10 [lacuna] ethylene oxide (wetting agent)	0.75%
20	- neutral calcium lignosulfonate (dispersant)	12%
	- calcium carbonate (inert filler)	qs 100%

Example WP 3:

25 This wettable powder contains the same ingredients as in the above example, in the following proportions:

	- active material	75%
--	-------------------	-----



- wetting agent 1.50%
- dispersant 8%
- calcium carbonate (inert filler) qs 100%

Example WP 4:

- 5 - active material 90%
- ethoxylated fatty alcohol
(wetting agent) 4%
- ethoxylated phenylethylphenol
(dispersant) 6%

10 Example WP 5:

- active material 50%
- mixture of anionic and nonionic
surfactants (wetting agent) 2.5%
- sodium lignosulfonate (dispersant) 5%
- 15 - kaolin clay (inert support) 42.5%

The aqueous emulsions and dispersions, for example the compositions obtained by diluting a wettable powder or an emulsifiable concentrate according to the invention with water, are included in
20 the general context of the present invention. The emulsions can be of water-in-oil or oil-in-water type and they can have a thick consistency such as that of a "mayonnaise".

The compounds according to the invention can
25 be formulated in the form of water-dispersible granules, which are also included in the context of the invention.

These dispersible granules, with an apparent



density generally of between about 0.3 and 0.6, have a particle size generally of between about 150 and 2000 microns and preferably between 300 and 1500 microns.

5 The active material content of these granules is generally between about 1% and 90% and preferably between 25% and 90%.

 The rest of the granule is composed essentially of a solid filler and optionally of
10 surfactant adjuvants which give the granule water-dispersibility properties. These granules can be essentially of two distinct types depending on whether or not the filler selected is water-soluble. When the filler is water-soluble, it can be inorganic or,
15 preferably, organic. Excellent results have been obtained with urea. In the case of an insoluble filler, it is preferably inorganic, such as, for example, kaolin or bentonite. It is then advantageously accompanied by surfactants (in a proportion of from 2
20 to 20% by weight of the granule), more than half of which consists, for example, of at least one dispersant, which is essentially anionic, such as an alkali metal or alkaline-earth metal polynaphthalene sulfonate or an alkali metal or alkaline-earth metal
25 lignosulfonate, the remainder consisting of nonionic or anionic wetting agents such as an alkali metal or alkaline-earth metal alkyl naphthalene sulfonate.

Moreover, although this is not essential,



other adjuvants such as antifoaming agents can be added.

The granule according to the invention can be prepared by mixing together the necessary ingredients, followed by granulation according to several techniques that are known per se (blender, fluid bed, atomizer, extrusion, etc.). The process generally ends by a crushing operation, followed by screening to the particle size chosen within the range mentioned above. Granules obtained as above and then impregnated with a composition containing the active material can also be used.

Preferably, the granule is obtained by extrusion, working as indicated in the examples below.

Example DG1: Dispersible granules

90% by weight of active material and 10% of urea pellets are mixed together in a mixer. The mixture is then ground in a spindle mill. A powder is obtained which is moistened with about 8% by weight of water. The wet powder is extruded through a perforated-roll extruder. A granulate is obtained, which is dried and then crushed and screened, so as to retain only the granules between 150 and 2000 microns in size, respectively.

Example DG2: Dispersible granules

The constituents below are mixed together in a mixer:

- active material

75%



- wetting agent (sodium alkyl-naphthalene sulfonate) 2%
- dispersant (sodium polynaphthalene sulfonate) 8%
- 5 - water-insoluble inert filler (kaolin) 15%

This mixture is granulated in a fluid bed in the presence of water, then dried, crushed and screened so as to obtain granules between 0.15 and 0.80 mm in
10 size.

These granules can be used alone, or in solution or dispersion in water so as to obtain the desired dose. They can also be used to prepare combinations with other active materials, in particular
15 antibacterial agents, the latter being in the form of wettable powders or aqueous suspensions or granules.

As regards the compositions which are suitable for storage and transportation, they more advantageously contain from 0.5 to 95% (by weight) of
20 active substance.

The invention also relates to a process for the therapeutic antibacterial treatment of man or animals by administration of an effective dose of the peptide according to the invention, in free form or,
25 where appropriate, in the form of addition salts with an acid, Andallic salts or addition salts with a base which are pharmaceutically acceptable, in pure form or in the form of a composition in which it is combined



with any other pharmaceutically compatible product,
which can be inert or physiologically active. The
medicaments according to the invention can be
administered orally, parenterally, rectally or
5 topically.

Tablets, pills, powders (in particular in
gelatin capsules or cachets) or granules can be used as
solid compositions for oral administration. In these
compositions, the active product according to the
10 invention is mixed with one or more inert diluents,
such as starch, cellulose, sucrose, lactose or silica.
These compositions can also comprise other substances,
for example one or more lubricants such as magnesium
stearate or talc, a dye, a coating (dragees) or a
15 glaze.

Pharmaceutically acceptable solutions,
suspensions, emulsions, syrups and elixirs containing
inert diluents such as water, ethanol, glycerol, plant
oils or liquid paraffin can be used as liquid
20 compositions for oral administration. These
compositions can also comprise other substances, for
example wetting products, sweeteners, thickeners,
flavorings or stabilizers.

The sterile compositions for parenteral
25 administration can preferably be emulsions, suspensions
or aqueous or non-aqueous solutions. Water, propylene
glycol, a polyethylene glycol, plant oils, in
particular olive oil, and suitable organic esters can



be used as solvent or vehicle. These compositions can also contain adjuvants, in particular wetting agents, tonicity agents, emulsifiers, dispersants and stabilizers. The sterilization can be carried out in different ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved in an injectable sterile medium at the time of use.

The compositions for rectal administration are suppositories or rectal capsules which contain, besides the active peptide, excipients such as cocoa butter, semi-synthetic glycerides or polyethylene glycols.

The sterile compositions for topical administration can be, for example, creams, ointments, lotions, eyedrops, mouthwashes, nasal drops or aerosols.

In human therapy, the peptide according to the invention is particularly useful in antibacterial treatments. The doses depend on the desired effect and the duration of the treatment; they are generally between 50 and 1000 mg per day via the oral route for an adult, taken in one or more doses.

In general, the doctor will determine the dosage which he or she considers to be the most appropriate, depending on the age and weight and all



the other personal factors of the individual to be treated.

The examples which follow, which are given without any limitation being implied, illustrate the compositions according to the invention.

Example A:

Tablets containing a 50 mg dose of active peptide and having the following composition are prepared according to the usual technique:

10	- androctonine peptide M1	50 mg
	- starch	60 mg
	- lactose	50 mg
	- magnesium stearate	2 mg

Example B:

15 An injectable solution containing 20 mg of active peptide and having the following composition is prepared:

	- androctonine peptide M 2	22.4 mg
	- distilled water	qs 2 cm ³

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that prior art forms part of the common general knowledge in Australia.



Arg Ser Val Cys Arg Gln Ile Lys Ile Cys Arg
Tyr Pro Arg Asn Thr Cys Lys Tyr Tyr Cys Gly Gly

3. The composition as claimed in claim 2,
which can be used to protect plants against pathogenic
bacteria.

5. An antifungal composition which contains as active material a peptide as claimed in claim 1.

7. The composition as claimed in claim 5, which can be used for the therapeutic treatment of the human or animal body.

9. A process for protecting plants against fungal diseases, in which a peptide as claimed in claim



1 is applied as active material.

10. A process for preparing the peptide as claimed in claim 1, in which the following are successively carried out:


- 5 a) hemolymph is taken from the scorpion *Androctonus australis*;
- b) extraction is carried out by placing the *Androctonus australis* hemolymph or grindings obtained above in contact with an acidic medium, with stirring, followed by centrifugation;
- 10 c) the supernatant is fractionated with separation by washing of the hydrophilic molecules and elution of the hydrophobic molecules with appropriate components on a separating column;
- 15 d) the extracts are purified;
- e) sequencing is carried out.

DATED this 9th day of June, 2000

RHONE-POULENC AGRO
by its Patent Attorneys
DAVIES COLLISON CAVE



1. Peptide having the following formula:



10 2. Antibacterial composition, characterized in that it contains, as an active ingredient, a peptide according to Claim 1.

3. Composition according to Claim 2, capable of being utilized to protect plants against pathogenic bacteria.

4. Composition according to Claim 2, capable of being utilized in the therapeutic treatment of the human or animal body.

5. Antifungal composition characterized in that it contains, as an active ingredient, a peptide
20 according to Claim 1.

6. Composition according to Claim 5, capable of being utilized to protect plants against pathogenic bacteria.

25 7. Composition according to Claim 5, capable of being utilized in the therapeutic treatment of
the human or animal body.

8. Procedure for the protection of plants against bacterial diseases, characterized in that, as an active ingredient, a peptide according to Claim 1 is applied.

9. Procedure for the protection of plants against fungal diseases, characterized in that, as an active ingredient, a peptide according to Claim 1 is applied.

10. Procedure for the preparation of the peptide according to Claim 1, characterized in that,
35 successively:

- a) Hemolymph is taken from the *Androctonus australis* scorpion;
- b) Extraction is performed by placing hemolymph or finely ground material, as previously obtained from *Androctonus australis*, in contact with an acidic-to-neutral solution, first via stirring and then via centrifugation;
- 5 c) The supernatant liquid is fractionated, with separation via the washing of the hydrophilic molecules and elution of the hydrophobic molecules, through the use of appropriate agents, on a separation column;
- d) The extracts are purified; and
- e) Sequencing is performed.